RAGE and the pathogenesis of chronic kidney disease (Q37737557)

22 August 2017

1 reference

title

RAGE and the pathogenesis of chronic kidney disease (English)

1 reference

22 August 2017

0 references

2

Ann Marie Schmidt

1 reference

22 August 2017

Vivette D'Agati

1

1 reference

PubMed ID

20421886

22 August 2017

language of work or name

English

0 references

publication date

27 April 2010

1 reference

Nature Reviews Nephrology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

352-360

1 reference

22 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.54

22 August 2017

0 references

cites work

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

The podocyte in diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Hyperglycemia and glycation in diabetic complications.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Antioxidant enzymes and lipoperoxide in blood in uremic children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Advanced glycation end product is implicated in amyloid-related kidney complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Renal and retinal effects of enalapril and losartan in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Microalbuminuria as a target to improve cardiovascular and renal outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Podocyte biology in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Mouse models of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Development of late-stage diabetic nephropathy in OVE26 diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Podocyte loss in aging OVE26 diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Metallothionein over-expression in podocytes reduces adriamycin nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Enhanced expression of receptor for advanced glycation end products in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE and modulation of ischemic injury in the diabetic myocardium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

The HMGB1 receptor RAGE mediates ischemic brain damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

The inflammatory response to ischemic acute kidney injury: a result of the 'right stuff' in the 'wrong place'?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE polymorphisms, renal function and histological finding at 12 months after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Genome-wide association study identifies five loci associated with lung function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Identification, classification, and expression of RAGE gene splice variants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Severity of diabetic microvascular complications is associated with a low soluble RAGE level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Soluble receptor for advanced glycation end products in patients with decreased renal function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Soluble RAGE, diabetic nephropathy and genetic variability in theAGERgene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

(Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Oxidative stress-induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.54

Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20421886

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20421886

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEPH.2010.54

1 reference

22 August 2017

1 reference

PubMed ID

20421886